The pharmacy benefit manager Prime Therapeutics released a study in October stating that findings indicate in the real world that individuals taking GLP-1 therapies without diabetes [over a two year period] will see no medical cost offset. Analysis of health insurance claims showed that the treatments did not lower other medical costs
On the surface, these simple shots pack a big yet expensive punch (more than $12,000 per person annually)
The 2.5 mg starting dose of tirzepatide activates two receptor pathways that naturally suppress hunger and increase fullness signals to your brain
- Suppress appetite - Slow gastric emptying (food stays in the stomach longer) - Increase feelings of fullness - Reduce calorie intake, often dramatically - Fast initial weight loss - Reduced cravings - Easier adherence to a calorie deficit in the short term From a purely scale-based perspective, GLP-1 medications can appear very effective
Pathophysiologic Context In PAH + HFpEF overlap: * ETA receptors drive vasoconstriction, hypertrophy, and fibrosis * ETB receptors mediate endothelin clearance, nitric oxide release, and natriuresis * HFpEF patients rely on ETB signaling to maintain volume balance and endothelial function Blocking ETB in HFpEF increases the risk of fluid retention and rising leftsided filling pressures
